Newsletter Tool

Today's Rundown

Biogen CEO Michel Vounatsos points to inherent risk in neuroscience as 3 programs cut
Takeda weaves F-star tech into patchwork of cancer capabilities, landing license for bispecific program
Adial at a clinical fork in the road after flunking phase 3 trial for its alcohol addiction med
Equipped with fresh $100M, CAMP4 heads up trail to the clinic, hoping partners will soon tag along
Big Pharmas Amgen, BMS shield BigHat from stormy market with $75M funding
Panic infects VBL investors as viral therapy flunks phase 3 cancer test
With hopes of paving new path for cancer treatment, Eli Lilly-backed Auron raises $48M
Labcorp to hike clinical trial kit capacity to meet EMEA demand
TetraScience expands cloud platform to include manufacturing, QC data
Merck's Keytruda posts rare flop in head and neck cancer trial
Dobbs decision 'opened the door for complete and utter chaos,' physicians and legal experts tell Congress
With new CEO, Invitae lays off more than 1,000 employees, slims international footprint
Novartis shelves a PD-1 bid in non-small cell lung cancer after FDA feedback

Featured Story

Biogen CEO Michel Vounatsos points to inherent risk in neuroscience as 3 programs cut

By Annalee Armstrong

In a sign of just how tough neuroscience is, Biogen is cutting a clutch of programs from its Alzheimer’s disease, amyotrophic lateral sclerosis and schizophrenia pipelines.

Let’s make clinical trials fluid and frictionless

What if you could break the chain of linear clinical trial design and move faster? With ZAIDYN™ Clinical Development, you can—by clearing barriers and connecting teams with insights that will shape the future of clinical research. Learn more.

Takeda weaves F-star tech into patchwork of cancer capabilities, landing license for bispecific program

By Nick Paul Taylor

Takeda has added another piece to the patchwork of bispecific antibody capabilities it's sewn together over the past 18 months, tapping F-star Therapeutics to support an immuno-oncology program.

Adial at a clinical fork in the road after flunking phase 3 trial for its alcohol addiction med

By Max Bayer

Adial flunked a phase 3 trial for its alcohol abuse treatment but says it accrued enough encouraging data that it will march to regulators anyway. The feedback will guide future development and partnership plans.

Equipped with fresh $100M, CAMP4 heads up trail to the clinic, hoping partners will soon tag along

By Max Bayer

A year after raising $45 million, CAMP4 is back for more, tacking on $100 million in a series B round. The funds will provide further financial cushion as the company sets its sights on the clinic in 2023.

Big Pharmas Amgen, BMS shield BigHat from stormy market with $75M funding

By Gabrielle Masson

BigHat Biosciences just capped off an $75 million series B to design safer, more effective antibody therapies, with Big Pharmas Amgen and Bristol Myers Squibb both joining the round as new investors.

Panic infects VBL investors as viral therapy flunks phase 3 cancer test

By Nick Paul Taylor

Look out below, VBL Therapeutics’ stock is coming crashing down. The failure of its viral-based therapy to hit either primary endpoint in a phase 3 ovarian cancer trial drove the biotech to stop the study and caused investors to flee.

With hopes of paving new path for cancer treatment, Eli Lilly-backed Auron raises $48M

By Gabrielle Masson

Auron Therapeutics has exited stealth mode with $48 million and backing from Big Pharma Eli Lilly, touting a new machine-learning platform and lofty hopes to flip the current cancer treatment paradigm on its head.

Labcorp to hike clinical trial kit capacity to meet EMEA demand

By Gareth Macdonald

Labcorp will expand specimen collection kit production at its plant in Belgium to cater for growing demand in Europe, the Middle East and Africa.

TetraScience expands cloud platform to include manufacturing, QC data

By Gareth Macdonald

TetraScience has added capacity for manufacturing and quality control data to its cloud-based software platform.

Merck's Keytruda posts rare flop in head and neck cancer trial

By Fraiser Kansteiner

Alongside chemoradiation therapy, Merck’s PD-1 inhibitor Keytruda failed to meet its primary endpoint in a late-stage trial for unresected locally advanced head and neck squamous cell carcinoma. While the drug did chart improvements in event-free survival, or the time a patient remains free of complications, the results weren’t statistically significant.

Dobbs decision 'opened the door for complete and utter chaos,' physicians and legal experts tell Congress

By Dave Muoio

The majority of clinical and legal witnesses testifying to lawmakers Tuesday outlined dangerous restrictions to reproductive and other care that have become more frequent amid an uncertain legal environment.

With new CEO, Invitae lays off more than 1,000 employees, slims international footprint

By Andrea Park

Genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company hundreds of millions of dollars annually.

Novartis shelves a PD-1 bid in non-small cell lung cancer after FDA feedback

By Zoey Becker

Shortly after the FDA delayed a tislelizumab decision in previously treated esophageal squamous cell carcinoma, Novartis is scrapping the drug's submission as a monotherapy for non-small cell lung cancer.